Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
More News: Abatacept | Actemra | Arthritis | Canada Health | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Health Insurance | Heart | Heart Attack | Heart Failure | Insurance | Orencia | Rheumatoid Arthritis | Rheumatology | Rituxan | Stroke | Study